title: Yellow fever: epidemiology and prevention.
abstract: Yellow fever continues to occur in regions of Africa and South America, despite the availability of effective vaccines. Recently, some cases of severe neurologic disease and multiorgan system disease have been described in individuals who received yellow fever vaccine. These events have focused attention on the need to define criteria for judicious use of yellow fever vaccine and to describe the spectrum of adverse events that may be associated with yellow fever vaccine. Describing host factors that would increase risk of these events and identifying potential treatment modalities for yellow fever and yellow fever vaccine-associated adverse events are subjects of intense investigation.
authors.affiliation: Maxwell Finland Laboratory for Infectious Diseases, Boston Medical Center, Boston, MA 02118, USA. ebarnett@bu.edu
authors.forename: Elizabeth D
authors.initials: ED
authors.lastname: Barnett
mesh_terms: D000293:Adolescent; D000328:Adult; D021821:Communicable Diseases, Emerging / Q000453:epidemiology / Q000517:prevention & control; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000209:etiology; D009422:Nervous System Diseases / Q000209:etiology; D018570:Risk Assessment; D012720:Severity of Illness Index; D013019:South Africa / Q000453:epidemiology; D013020:South America / Q000453:epidemiology; D014195:Travel; D014611:Vaccination / Q000009:adverse effects* / Q000379:methods; D015004:Yellow Fever / Q000453:epidemiology* / Q000517:prevention & control*; D022341:Yellow Fever Vaccine / Q000008:administration & dosage / Q000009:adverse effects*; D015005:Yellow fever virus / Q000302:isolation & purification
chemical_list: D022341:Yellow Fever Vaccine